Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BIO Creates Policy Chief Position, Plans Reports Justifying Biotech Prices

Executive Summary

The Biotechnology Industry Organization is continuing to expand its reach into the health policy arena with the creation of a "chief of policy" position

You may also be interested in...

Humatrope And Human Enhancement: Lilly Drug Featured In Bioethics Report

FDA's approval of Humatrope for idiopathic short stature plays a prominent role in a report by the President's Council on Bioethics as an example of the blurry line between medical need and human enhancement

CMS “Functional Equivalence” Standard Targeted In Medicare Bills

CMS would be prohibited from using the Aranesp/ Procrit "functional equivalence" decision as a precedent in future reimbursement rulings under both the House and Senate versions of the Medicare prescription drug bill

Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule

The National Cancer Institute will conduct a head-to-head study of Amgen's Aranesp (darbepoetin) and Ortho's Procrit (epoetin) in order to define equivalent doses of the anemia agents, CMS reports in the final Hospital Outpatient Prospective Payment System rule for 2003




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts